Gian Lifecare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 22, 2025, 8:51 am

Competitors of Gian Lifecare Ltd

All Competitor Stocks of Gian Lifecare Ltd

Quarterly Result

Last Updated: July 18, 2025, 2:52 pm

Below is a detailed analysis of the quarterly data for Gian Lifecare Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

• For Sales, as of Dec 2024, the value is 1.59 Cr.. The value appears to be declining and may need further review. It has decreased from 1.95 Cr. (Sep 2024) to 1.59 Cr., marking a decrease of 0.36 Cr..
• For Expenses, as of Dec 2024, the value is 1.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.72 Cr. (Sep 2024) to 1.11 Cr., marking a decrease of 0.61 Cr..
• For Operating Profit, as of Dec 2024, the value is 0.48 Cr.. The value appears strong and on an upward trend. It has increased from 0.23 Cr. (Sep 2024) to 0.48 Cr., marking an increase of 0.25 Cr..
• For OPM %, as of Dec 2024, the value is 30.19%. The value appears strong and on an upward trend. It has increased from 11.79% (Sep 2024) to 30.19%, marking an increase of 18.40%.
• For Other Income, as of Dec 2024, the value is 0.16 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.16 Cr..
• For Interest, as of Dec 2024, the value is 0.10 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.10 Cr..
• For Depreciation, as of Dec 2024, the value is 0.12 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.12 Cr..
• For Profit before tax, as of Dec 2024, the value is 0.42 Cr.. The value appears strong and on an upward trend. It has increased from 0.17 Cr. (Sep 2024) to 0.42 Cr., marking an increase of 0.25 Cr..
• For Tax %, as of Dec 2024, the value is 9.52%. The value appears to be improving (decreasing) as expected. It has decreased from 11.76% (Sep 2024) to 9.52%, marking a decrease of 2.24%.
• For Net Profit, as of Dec 2024, the value is 0.38 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Sep 2024) to 0.38 Cr., marking an increase of 0.24 Cr..
• For EPS in Rs, as of Dec 2024, the value is 0.37. The value appears strong and on an upward trend. It has increased from 0.14 (Sep 2024) to 0.37, marking an increase of 0.23.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:15 am

Growth

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: October 10, 2025, 4:09 pm

Below is a detailed analysis of the balance sheet data for Gian Lifecare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.34 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.34 Cr..
• For Reserves, as of Mar 2025, the value is 9.42 Cr.. The value appears strong and on an upward trend. It has increased from 9.27 Cr. (Mar 2024) to 9.42 Cr., marking an increase of 0.15 Cr..
• For Borrowings, as of Mar 2025, the value is 5.07 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4.17 Cr. (Mar 2024) to 5.07 Cr., marking an increase of 0.90 Cr..
• For Other Liabilities, as of Mar 2025, the value is 10.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.28 Cr. (Mar 2024) to 10.73 Cr., marking an increase of 2.45 Cr..
• For Total Liabilities, as of Mar 2025, the value is 35.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.06 Cr. (Mar 2024) to 35.56 Cr., marking an increase of 3.50 Cr..
• For Fixed Assets, as of Mar 2025, the value is 4.01 Cr.. The value appears to be declining and may need further review. It has decreased from 4.47 Cr. (Mar 2024) to 4.01 Cr., marking a decrease of 0.46 Cr..
• For CWIP, as of Mar 2025, the value is 0.14 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.14 Cr..
• For Investments, as of Mar 2025, the value is 0.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.11 Cr..
• For Other Assets, as of Mar 2025, the value is 31.30 Cr.. The value appears strong and on an upward trend. It has increased from 27.34 Cr. (Mar 2024) to 31.30 Cr., marking an increase of 3.96 Cr..
• For Total Assets, as of Mar 2025, the value is 35.56 Cr.. The value appears strong and on an upward trend. It has increased from 32.06 Cr. (Mar 2024) to 35.56 Cr., marking an increase of 3.50 Cr..

Notably, the Reserves (9.42 Cr.) exceed the Borrowings (5.07 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Gian Lifecare Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 4.02 (Mar 24) to -0.03, marking a decrease of 4.05.
• For Diluted EPS (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 4.02 (Mar 24) to -0.03, marking a decrease of 4.05.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 3. It has decreased from 4.53 (Mar 24) to 0.57, marking a decrease of 3.96.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.59. It has decreased from 18.64 (Mar 24) to 18.59, marking a decrease of 0.05.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.59. It has decreased from 18.64 (Mar 24) to 18.59, marking a decrease of 0.05.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.41. It has decreased from 12.69 (Mar 24) to 6.41, marking a decrease of 6.28.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 6.52 (Mar 24) to 1.14, marking a decrease of 5.38.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.53. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 0.53, marking a decrease of 5.47.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 5.56 (Mar 24) to 0.03, marking a decrease of 5.53.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 2. It has decreased from 4.01 (Mar 24) to -0.03, marking a decrease of 4.04.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 2. It has decreased from 4.01 (Mar 24) to -0.03, marking a decrease of 4.04.
• For PBDIT Margin (%), as of Mar 25, the value is 17.78. This value is within the healthy range. It has decreased from 51.38 (Mar 24) to 17.78, marking a decrease of 33.60.
• For PBIT Margin (%), as of Mar 25, the value is 8.30. This value is below the healthy minimum of 10. It has decreased from 47.34 (Mar 24) to 8.30, marking a decrease of 39.04.
• For PBT Margin (%), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 10. It has decreased from 43.80 (Mar 24) to 0.57, marking a decrease of 43.23.
• For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has decreased from 31.64 (Mar 24) to -0.56, marking a decrease of 32.20.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 8. It has decreased from 31.64 (Mar 24) to -0.56, marking a decrease of 32.20.
• For Return on Networth / Equity (%), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 15. It has decreased from 21.54 (Mar 24) to -0.19, marking a decrease of 21.73.
• For Return on Capital Employeed (%), as of Mar 25, the value is 2.35. This value is below the healthy minimum of 10. It has decreased from 27.51 (Mar 24) to 2.35, marking a decrease of 25.16.
• For Return On Assets (%), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from 12.72 (Mar 24) to -0.10, marking a decrease of 12.82.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.30, marking an increase of 0.05.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has decreased from 0.43 (Mar 24) to 0.19, marking a decrease of 0.24.
• For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.31 (Mar 24) to 1.45, marking an increase of 0.14.
• For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 1.40, marking an increase of 0.18.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.82. This value exceeds the healthy maximum of 8. It has increased from 2.00 (Mar 24) to 8.82, marking an increase of 6.82.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 3. It has decreased from 14.54 (Mar 24) to 2.30, marking a decrease of 12.24.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 3. It has decreased from 9.96 (Mar 24) to 0.92, marking a decrease of 9.04.
• For Enterprise Value (Cr.), as of Mar 25, the value is 16.65. It has decreased from 24.19 (Mar 24) to 16.65, marking a decrease of 7.54.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.51. This value is within the healthy range. It has increased from 1.84 (Mar 24) to 2.51, marking an increase of 0.67.
• For EV / EBITDA (X), as of Mar 25, the value is 14.12. This value is within the healthy range. It has increased from 3.59 (Mar 24) to 14.12, marking an increase of 10.53.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 2.68, marking an increase of 0.75.
• For Price / BV (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.92, marking a decrease of 0.39.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 2.68, marking an increase of 0.75.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness